Rctd-444 -

Published on April 17, 2026

– A small blood draw (≈10 ml) or skin biopsy is taken. The sample is sent to the IRC’s GMP‑compliant cell‑manufacturing facility. RCTD-444

The at IRC is already in early dialogue with the FDA’s Office of Cellular, Tissue, and Gene Therapies (OCTGT), leveraging the agency’s 2022 guidance on combination products (cellular + device + gene‑editing) to streamline the review. Published on April 17, 2026 – A small